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The approval of sildenafil citrate (Viagra 1 ) in over 110 countries, including Mexico and several countries in South America, has greatly increased the awareness of ED as a medical condition and its treatment. Sildenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP) -specific phosphodiesterase type 5 (PDE5), the predominant enzyme that metabolizes cGMP in the corpus cavernosum. 3 Through this action, sildenafil enhances cGMP-mediated relaxation of corpus cavernosum smooth muscle, thereby enhancing penile erectile responses to sexual stimulation. After oral administration, the drug is rapidly absorbed, 4 with an appropriate duration of therapeutic activity that is convenient for most couples. 5 Numerous double-blind, placebo-controlled trials conducted worldwide have demonstrated that, in men with ED of organic, psychogenic, or mixed etiologies, sildenafil significantly improves the ability to achieve and maintain erections and successfully engage in sexual intercourse. 6 In this patient population, the use of sildenafil has also been associated with significant improvement in quality of life. 7 Data also suggest the efficacy of sildenafil in special subsets of patients, including those with concomitant type 1 or type 2 diabetes, treated hypertension, depression, end-stage renal disease maintained with hemodialysis, or spinal cord injury. 6, 8 Safety analyses indicate that, provided sildenafil is not prescribed for patients taking organic nitrates, the drug is well tolerated with low rates of discontinuation. The inhibitory effects of sildenafil on PDE5 can result in occurrences of mild to moderate headache, flushing, dyspepsia, or nasal congestion. 3, 9 The partial inhibition of cGMPdependent PDE6 in the photoreceptor cells of the retina 10 can result in a low incidence of reversible, mild visual changes, typically described as a color tinge to vision, increased sensitivity to light, or blurred vision. 9 These visual effects are dose-related and have not been associated with long-term sequelae. 6 Regional and cultural aspects play an important role in human sexuality and, although a large number of publications have appeared in the literature in the last 5 years, little is known about the status or treatment of ED in the Latin American population. In this supplement, several papers are presented that provide an overview of the epidemiology of ED in different regions of Latin America and the clinical experience with sildenafil for the treatment of men with ED residing in these regions.
Two papers in this supplement present the results of population-based studies determining the prevalence and correlates of ED in northeastern Brazil and in the northern region of South America represented by Colombia, Ecuador, and Venezuela. The results of these studies indicate that, as in other countries, ED is a common problem among Latin American men. The overall prevalence of ED was found to be approximately 40% in northeastern Brazil and over 50% in Colombia, Ecuador, and Venezuela. A third study determined the prevalence and correlates of ED in a subset of 118 Brazilian men with end-stage renal failure maintained on hemodialysis. This study found the prevalence of moderate or complete ED to be approximately 50% among men between the ages of 18 and 49 y, increasing to 70% among men aged 50 y or older. These confirm previous reports of high overall prevalence rates for ED among this patient population (82%). 11 As in the USA, 2 in Latin American countries, increasing age was found to be a consistently strong correlate of ED. Other prominent risk factors for ED were diabetes and hypertension in northern countries of South America and diabetes and heart disease among the Brazilian men with end-stage renal failure.
Also reported in this supplement are the results of three double-blind, placebo-controlled, multicenter, 12-week studies that evaluated the efficacy and safety of sildenafil in Latin American men with ED and the results of a fourth open-label multicenter trial comparing the efficacy and safety of sildenafil and oral phentolamine, an approved treatment for ED in Brazil and Mexico. The placebo-controlled studies were conducted in three distinct geographical regions of Latin America, including Brazil and Mexico, the northern part of South America represented by Colombia, Ecuador, and Venezuela, and the southern area of South America represented by Argentina, Chile, Peru, and Uruguay. All three trials allowed flexibility in sildenafil dose (25, 50, or 100 mg) and included men with ED of various etiologies, excluding spinal cord injury. These studies attempted to approximate the average clinical setting and included patients with a variety of concomitant risk factors for ED. In the studies conducted in Brazil=Mexico and the southern countries of South America, approximately 27% and 36% of respective patients had concomitant hypertension, and approximately 20% and 17% of respective patients had well-controlled type 1 or type 2 diabetes mellitus. Approximately 40% of the participants in the southern Latin American study were current smokers. The primary efficacy measures in these studies were the ability to achieve (question 3 of the International Index of Erectile Function [IIEF]) and maintain an erection (question 4 of the IIEF). 12 Consistent with efficacy results of controlled studies in North American and European populations with ED, 6 all of the three controlled studies in the Latin American populations found sildenafil to be an effective and well-tolerated oral treatment for ED.
The open-label comparison between sildenafil (25 -100 mg) and oral phentolamine (40 mg) as treatment for mild or moderate ED was conducted in 17 centers in Mexico. The primary efficacy measure was the erectile function domain of the IIEF. After 8 weeks of treatment, the sildenafil group showed significant improvement in erectile function, compared with the phentolamine group. Attempts at sexual intercourse were successful in approximately 87% of sildenafil-treated men, compared with 41% of phentolamine-treated men. In addition to its superiority in efficacy, sildenafil was also better tolerated than oral phentolamine.
The final paper in this supplement gives an overview of the safety profile for sildenafil as treatment for ED in Latin American men. The analysis of the pooled safety data from the three placebo-controlled trials conducted in the different Latin American regions showed that sildenafil was well tolerated. The adverse-event profile in this patient sample was consistent with the profile from Phase II=III clinical trials conducted elsewhere. 9 Adverse events were generally transient and mild and rarely resulted in treatment discontinuation.
Based on the findings of the studies presented in this supplement, it can be concluded that, as in other male populations, ED is a common problem among Latin American men. In Latin American men with ED, sildenafil is effective and safe, showing efficacy and safety profiles comparable to that shown in studies of other patient populations.
